DAR No 5: Umeclidinium bromide. Incruse® for COPD

Content tools

Share it

Very little efficacy

Umeclidinium is a long acting muscarinic antagonist (LAMA) authorized for symptom relief in patients with Chronic Obstructive Pulmonary Disease (COPD).
They are no comparative data available with tiotropium, or with other LAMA or LABA.
It has not shown to reduce the number of exacerbations. Neither does it improve quality of life or reduce the need for rescue treatment in studies lasting more than 12 weeks.
There is concern on safety regarding its cardiovascular profile and the possible higher risk of pneumonia.

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *